dmc1:IR Board of Directorsdmc2:Board Of DirectorsArray ( [0] => member-category )
dmc1 cat array 0:member-category PT:member
gpt:member
Array ( )
Kleanthis G. Xanthopoulos, Ph.D.

Kleanthis G. Xanthopoulos, Ph.D.

Board Member, President and CEO

back

Born in 1958. Member of the Board since 2015. President and CEO since 2015.

Education and relevant experience:

Kleanthis G. Xanthopoulos holds an M.Sc. and a Ph.D. in Molecular Biology from Stockholm University and was an Associate Professor at Karolinska Institute in Stockholm, Sweden. Kleanthis G. Xanthopoulos has
more than 25 years’ experience from operational positions in the life science sector. Kleanthis G. Xanthopoulos also has extensive experience as an investor in life science companies in the United States and the European Union and has founded four life science companies, of which two (excluding IRRAS) have been listed at NASDAQ (Anadys Pharmaceuticals, Inc. which was acquired by F. Hoffmann-La Roche Inc. for USD 230 million in 2011, and Regulus Therapeutics Inc). Kleanthis G. Xanthopoulos has also financed and brokered numerous creative strategic alliance and partnership deals with large pharmaceutical partners.

Other current assignments:

Chairman of the board of Apricus Biosciences Inc., board member of ZosanoPharma Inc., and Sente Inc. Management member in Cerus Advisors DMCC and President of Helios Inc.

Holdings in IRRAS:

Shareholding: 367 275 shares
Warrants: 1 275 000 warrants under the 2016/2020 warrant scheme
Share award program: The share award program entitles Dr Xanthopoulos to 475 604 shares when a 510 (k) clearance is received